Latest in Cardiology from ACC.org

• ACC CardioSurve: How is Telehealth Being Used Post COVID-19 Pandemic?
  Based on findings from an ACC survey published Aug. 6 in Digital Health regarding cardiologists' perceptions towards the use of telehealth, some proposed clinical workflow models may offer guidance on when to best use telemedicine visits, potential resources required and the feasibility of remote visits for a variety of clinical encounters.
• From Polypills to Comorbidities: New Studies Help to Advance Understanding of HF Risks and Treatments
  Three newly published studies in JACC Journals examine key aspects of heart failure (HF): a multi-level polypill strategy for patients with HF with reduced ejection fraction (HFrEF); the impact of HF with preserved ejection fraction (HFpEF) on individuals with atrial fibrillation (AFib)...
• DapaTAVI Substudy: Does Dapagliflozin Improve Health Status Post TAVI?
  Although dapagliflozin may reduce death or worsening heart failure (HF) in patients with aortic stenosis (AS) undergoing TAVI, it showed limited improvement in patients' health status post TAVI, according to a prespecified subanalysis of the DapaTAVI trial published Oct. 6 in JACC.
• Eagle’s Eye View: A Look at ACC’s Scientific Statement on Inflammation and CVD
  In this week’s View, Dr. Eagle looks at an ACC Scientific Statement highlighting inflammation and its role in cardiovascular disease (CVD).
• JACC State-of-the-Art Review: Benefits of Anti-Inflammatories Post AMI
  A JACC State-of-the-Art Review provides a comprehensive and current overview of inflammatory mechanisms post-acute myocardial infarction (AMI) and evaluates the current evidence for anti-inflammatory therapies for secondary cardiovascular prevention.